The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.
The Taiwanese research team that developed the method showed in a new study that it could better detect BRAF mutations than conventional PCR plus Sanger sequencing.
By comparing pre-treatment and post-relapse samples from vemurafenib-treated melanoma patients, researchers uncovered resistance-related cohesin complex mutations.
Researchers also found that higher frequencies of BRAF V600E mutations in the blood were associated with poorer outcomes and less responsiveness to BRAF inhibitors.
When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.
A study of 54 patient samples showed castPCR was a sensitive and specific method to detect V600E and V600K mutations in melanomas.
Before patients receive the Cotellic/Zelboraf combination, patients should be tested with an FDA-approved BRAF mutation companion test, the agency said.
The company will use the money to develop liquid biopsy versions of its solid tumor BRAF and KRAS diagnostics as part of a larger research collaboration.
A team led by Memorial Sloan Kettering researchers showed advantages of the basket trial design in identifying precision treatment leads for rare cancer populations.
For some BRAF V600 mutation-positive cancers, BRAF V600 appears to be a targetable oncogene, a basket study shows.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.